Biotech Inscript

About Publications Sign in Subscribe

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Inceptive, founded by a former Google AI expert, secures $100M in funding from investors like Nvidia and Andreessen Horowitz to advance AI-driven biotech initiatives

Top Stories

Roche to Acquire Carmot Therapeutics in a $3.1 Billion Deal

Roche to acquire Carmot Therapeutics for $3.1B, gaining access to innovative obesity and diabetes treatments. The deal includes clinical-stage assets with potential for standalone and combination therapies. Expected to close in Q1 2024, pending regulatory approval.

Samsung Biologics and VC Firm Kurma Partners Announce Biologics Manufacturing Partnership for Kurma's Portfolio Companies

Samsung Biologics & Kurma Partners team up for biologics development & manufacturing, empowering startups in Kurma's portfolio with tailored CMC services & global expertise. A strategic partnership driving biopharmaceutical innovation.

Edesa Biotech Secures C$23 Million Canadian Govt. Funding to Accelerate Breakthrough Immune Treatment

Edesa Biotech secures C$23 million in government funding for Phase 3 clinical study of EB05, a pioneering immune therapy, as announced in their press release. The funding reinforces their commitment to advancing healthcare innovation.

Latest

Roche to Acquire Carmot Therapeutics in a $3.1 Billion Deal

Roche to Acquire Carmot Therapeutics in a $3.1 Billion Deal

Roche to acquire Carmot Therapeutics for $3.1B, gaining access to innovative obesity and diabetes treatments. The deal includes clinical-stage assets with potential for standalone and combination therapies. Expected to close in Q1 2024, pending regulatory approval.

Samsung Biologics and VC Firm Kurma Partners Announce Biologics Manufacturing Partnership for Kurma's Portfolio Companies

Samsung Biologics and VC Firm Kurma Partners Announce Biologics Manufacturing Partnership for Kurma's Portfolio Companies

Samsung Biologics & Kurma Partners team up for biologics development & manufacturing, empowering startups in Kurma's portfolio with tailored CMC services & global expertise. A strategic partnership driving biopharmaceutical innovation.

Edesa Biotech Secures C$23 Million Canadian Govt. Funding to Accelerate Breakthrough Immune Treatment

Edesa Biotech Secures C$23 Million Canadian Govt. Funding to Accelerate Breakthrough Immune Treatment

Edesa Biotech secures C$23 million in government funding for Phase 3 clinical study of EB05, a pioneering immune therapy, as announced in their press release. The funding reinforces their commitment to advancing healthcare innovation.

Pfizer-Backed VitaDAO Community Approves Launch and Financing of Its First Longevity Biotech Company

Pfizer-Backed VitaDAO Community Approves Launch and Financing of Its First Longevity Biotech Company

Pfizer-backed VitaDAO marks a milestone, launching Matrix Biosciences, their first longevity-focused biotech company, aiming to unlock breakthroughs in extending human life. Dr. Vera Gorbunova leads the venture, exploring the secrets of cancer-resistant naked mole-rats.

2023 Nobel Prize in Physiology or Medicine Awarded to Dr. Karikó and Dr. Weissman for Contributions to mRNA-based COVID-19 Vaccines

2023 Nobel Prize in Physiology or Medicine Awarded to Dr. Karikó and Dr. Weissman for Contributions to mRNA-based COVID-19 Vaccines

The 2023 Nobel Prize in Physiology or Medicine has been awarded to Dr. Katalin Karikó and Dr. Drew Weissman for their groundbreaking work in the development of mRNA-based COVID-19 vaccines.

Henlius Biotech's HANSIZHUANG (Serplulimab) Approved for Treatment of Esophageal Cancer (ESCC)

Henlius Biotech's HANSIZHUANG (Serplulimab) Approved for Treatment of Esophageal Cancer (ESCC)

Henlius Biotech's anti-PD-1 monoclonal antibody, HANSIZHUANG (Serplulimab), gains approval for treating PD-L1 positive esophageal cancer. Promising clinical results and a growing portfolio highlight its commitment to advancing cancer care worldwide.

Elon Musk's Neurotechnology Startup to Initiate Human Trial For Brain Implants

Elon Musk's Neurotechnology Startup to Initiate Human Trial For Brain Implants

Neuralink's PRIME Study, an FDA-approved brain-computer interface trial, aims to empower paralysis patients by wirelessly connecting their thoughts to devices. A milestone in merging technology and healthcare, it offers hope for enhanced independence.